Screener
Assembly Biosciences ASMB Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Efficiency | ||||||
| Asset turnover | 0.4×0.0× | 0.4×+0.1× | 0.4×+0.2× | 0.2×-0.2× | 0.3×+0.1× | |
| Liquidity | ||||||
| Current ratio | 14×+12.4× | 6.6×+4.6× | 5.2×+2.8× | 4.4×+2.1× | 1.6×-1.1× | |
| Leverage | ||||||
| Debt-to-equity | 0×-0.2× | 0×-0.1× | 0×-0.1× | 0×0.0× | 0.2×+0.1× | |
| Per Share | ||||||
| Book value per share | $16.21+586% | $11.75+225% | $18.44+232% | $14.40+252% | $2.36-61.5% | |
| Valuation | ||||||
| Market capitalization | $467.89M+157% | $440.19M+514% | $537.94M+436% | $196.41M+104% | $131.37M+50.9% | |
| Price / sales | 6.3×+1.4× | 6.2×+4.0× | 7.4×+3.9× | 5.3×+1.9× | 4×-0.1× | |
| Price / book | 1.5×+0.5× | 2.2×-0.4× | 2.6×-0.4× | 1.1×-2.6× | 7.3×+4.7× |
FAQ
- Where do Assembly Biosciences's ratios come from?
- Every ratio is computed from Assembly Biosciences's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
